Bibliography
- Senior R, Soman P, Khattar RS, Lahiri A. Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging. Am Heart J 1999;138:163-8
- Mulvagh SL, Rakowski H, Vannan MA. American society of echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2008;11:1179-201
- Main ML, Grayburn PA. Clinical applications of transpulmonary contrast echocardiography. Am Heart J 1999;137:144-53
- Geny B, Mettauer B, Muan B, et al. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol 1993;22:1193-8
- Feinstein SB, Cheirif J, Ten Cate, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 1990;16:316-24
- Crouse LJ, Cherif J, Hanly DE. Opacification and border delineation improvement in patients with suboptimal border definition in routine echocardiography: results of the Phase III Albunex multicenter trial. J Am Coll Cardiol 1993;22:1494-500
- Rainbird A, Mulvagh S, Oh H, et al. Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients. J Am Soc Echocardiogr 2001;14:78-385
- Vlassak I, Rubin D, Odabashian J. Contrast and harmonic imaging improves the accuracy and efficiency of novice readers for dobutamine stress echocardiography. Echocardiography 2002;19:483-8
- Dolan M, Riad K, El-Shafei A. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. Am Heart J 2001;142:908-15
- Thanigaraji S, Nease R, Schechtman K, et al. Use of contrast for image enhancement during stress echocardiograph is cost-effective and reduces additional diagnostic testing. Am J Cardiol 2001;87:1430-2
- Hundley GH, Kizilbash AM, Afridi I, et al. Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. J Am Coll Cardiol 998;32:1426-32
- Thompson HL, Basmadjian AJ, Rainbird AJ, et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective; randomly assigned, blinded study. J Am Coll Cardiol 2001;38:867
- Malm S, Frigstad S, Sagberg E, et al. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography. J Am Coll Cardiol 2004;44:1030-35
- Nayyar S, Magalski A, Khumri TM, et al. Contrast administration reduces interobserver variability in determination of left ventricular ejection fraction in patients with left ventricular dysfunction and good baseline endocardial border delineation. Am J Cardiol 2006;98:1110-4
- Cohen JL, Cheirif J, Segar DS, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. J Am Coll Cardiol 1998;32:746-52
- Skyba DM, Camarano G, Goodman BS, et al. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second generation ecohcardiographic contrast agent capable of producing myocardial opacification form a venous injection. J Am Coll Cardiol 1996;28:1292-300
- Kitzman DW, Goldman ME, Gillam LD, et al. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000;86:669-74
- Lindner JR, Song J, Jayaweera AR, et al. Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration. J Am Soc Echocardiogr 2002;15:396-403
- New US Food and Drug Administration prescribing information for Definity® approved October 10th 2007. Available from: http://www.fda.gov/cder/foi/label/2007/021064s007lbl.pdf [Accessed 13 October 2007]
- Hensley S. Warnings on ultrasound imaging drugs to turn black. Available from: http://blogs.wsj.com/health/2007;/10/07/warnings-on-ultrasound-imaging-drugs-to-turn-black/ [Accessed 13 October 2008]
- Main ML, Goldman JH, Grayburn PA. Thinking outside the “box”–the ultrasound contrast controversy. J Am Coll Cardiol 2007;50:2434-7
- Grayburn PA. Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration). Am J Cardiol 2008;101:892-3
- Douglas PS, Weyman AE, Lindner JR, Wei K. Contrast echocardiography: past, present, and future? J Am Coll Cardiol Img 2008;1:107-10
- Hildner FJ, Javier RP, Ramaswamy K. Pseudocomplications of cardiac catheterization. Chest 1973;63:15
- Hildner FJ, Javier RP, Tolentino A, Samet P. Pseuodocomplications of cardiac catheterization: update. Cathet Cardiovasc Diagn 1982;8:43
- Johnson LW, Lozner EC, Johnson S, et al. Coronary angiography 1984-1987: a report of the registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn 1989;17:5
- Stuart RJ Jr, Ellestad MH. National survey of exercise stress testing facilities. Chest 1980;77:94-7
- Picano E. Sustainability of medical imaging. BMJ 2004;328:578-80
- Einstein AJ, Moser KW, Thompson RC, et al. Radiation dose to patients from cardiac diagnostic testing. Circulation 2007;116:1290-305
- Seward JB, Khandheria BK, Oh JK, et al. Critical appraisal of transesophageal echocardiography: limitations, pitfalls, and complications. J Am Soc Echocardiogr 1992;5(3):228-305
- Marcovitz PA, Williamson BD, Armstrong WF. Toxic methemoglobinemia caused by topical anesthetic given before transesophageal echocardiography. J Am Soc Echocardiogr 1991;4:615
- Kornbluth M, Liang DH, Brown P, et al. Contrast echocardiography is superior to tissue harmonics for assessment of left ventricular function in mechanically ventilated patients. Am Heart J 2000;140:291-6
- Reilly JP, Tunick PA, Timmermans RJ, et al. Contrast echocardiography clairifies uninterpretable wall motion in intensive care unit patients. J Am Coll Cardiol 2000;35:485-90
- Yong Y, Wu D, Fernandes V, et al. Diagnostic accuracy and cost-effectiveness of contrast echocardiography on evaluation of cardiac function in technically very difficult patients in the intensive care unit. Am J Cardiol 2002;89:711-8
- Keen C. Ultrasound contrast advocates take aim at FDA black box warning. Available from: http://www.auntminnie.com/index.asp?Sec=sup&Sub=car&Pag=dis&ItemId=79499 [Accessed 13 October 2008]
- Wood S. FDA facing mounting pressure to rethink echo-contrast warning labels.theheart.org. [Clinical Conditions > Heart failure > Heart failure]; November 28, 2007. Accessed from: http://www.theheart.org/article/830665.do [Accessed 13 October 2008]
- Dixon BK. FDA gets flak for contrast warning. Int Med News 2008;41:1-5
- Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 patients. J Am Cardiol Coll 2008;51:1704-6
- Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent; multicenter results in 4,300,966 consecutive patients. Am J Cardiol 2008;102:1742-6
- Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA 2008;299;2023-5
- Wei K, Mulvagh SL, Carson L, et al. The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 2008;11:1202-6
- Dolan MS, Gala S, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography: a multicenter experience. J Am Coll Cardiol 2009;53(1):32-8
- Gabriel RS, Smyth YM, Menon V, et al. Safety of ultrasound contrast agents in stress echocardiography. Am J Cardiol 2008;102:1269-72
- Shaikh K, Chang SM, Peterson L, et al. Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress. Am J Cardiol 2008;102:1444-50
- FDA Advisory Committee briefing document for the Cardiovascular and Renal Drugs Advisory Committee June 24, 2008: safety considerations in the development of ultrasound contrast agents. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4369b1-01.pdf [Accessed 13 September 2008]
- Erb JM, Shanewise JS. Intraoperative contrast echocardiography with intravenous optison does not cause hemodynamic changes during cardiac surgery. J Am Soc Echocardiogr 2001;14:595-600
- Summary minutes of the Cardiovascular and Renal Drugs Advisory Committee June 24, 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4369m1-final.pdf [Accessed 13 September 2008]
- Stiles S. FDA panel tries to smooth out the bumps in echo contrast-agent approval decisions.theheart.org. [Clinical Conditions > Clinical cardiology > Clinical cardiology]; June 26, 2008. Available from: http://www.theheart.org/article/878433.do [Accessed 13 October 2008]
- Stiles S. FDA backpedals on warnings in echo-contrast labeling.theheart.org. [Clinical Conditions > Clinical cardiology > Clinical cardiology]; May 13, 2008. Available from: http://www.theheart.org/article/864915.do [Accessed 13 October 2008]
- United States Food and Drug Administration Center for Drug Evaluation and Research alert for healthcare providers updated on July 17, 2008. Available from: http://www.fda.gov/cder/drug/ infopage/microbubble/default.htm [Accessed 13 October 2008]
- US echo contrast agent use dips in Q2. Available from: http://www.auntminnie.com/index.asp?Sec=sup&Sub=bai&Pag=dis&ItemId=82115 [Accessed 13 October 2008]